<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="1480">
  <stage>Registered</stage>
  <submitdate>3/08/2006</submitdate>
  <approvaldate>18/08/2006</approvaldate>
  <actrnumber>ACTRN12606000355572</actrnumber>
  <trial_identification>
    <studytitle>Effect of barley foods on cardiovascular health biomarkers</studytitle>
    <scientifictitle>A randomised cross-over study of the effects of barley foods containing beta-glucans compared with whole wheat foods on cardiovascular health biomarkers, total cholesterol, HDL cholesterol, LDL cholesterol &amp; triglycerides in people with hypercholesterolaemia</scientifictitle>
    <utrn />
    <trialacronym>Barley</trialacronym>
    <secondaryid>Commonwealth Scientific Industrial Research Organisation (CSIRO): KR10A</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Hypercholesterolaemia</healthcondition>
    <conditioncode>
      <conditioncode1>Blood</conditioncode1>
      <conditioncode2>Other blood disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>All participants at the start of the study will be on a fat controlled diet for 2 week prior to being randomised to 1 of 2 treatments of 6 weeks duration each &amp; crossed over at the end of each 6 weeks to the alternative. The treatments are either test foods (cereal, bread muffins) containing either barley flour or wholemeal wheat flour. There is no wash-out period between treatments.</interventions>
    <comparator />
    <control>Active</control>
    <interventioncode>Lifestyle</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Fasting lipids</outcome>
      <timepoint>At weeks 2, 8 and 14</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Glucose &amp; insulin</outcome>
      <timepoint>At weeks 2, 8 &amp; 14</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Have a fasting plasma triglyceride concentration greater than 1.7mmol/L but less than 4.0 mmol/L, and/or plasma cholesterol greater than 5.5 mmol/L.Are taking cholesterol-lowering drugs provided the dose of medication remains stable for the duration of the study.</inclusivecriteria>
    <inclusiveminage>30</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>75</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>:Have a definite or suspected personal or family history of adverse events or hypersensitivity to barley or wheat (eg. coeliac disease)Suffer from bleeding disordersAre considered by the doctor or dietitian to be unwilling, unlikely or unable to comprehend or comply with the study protocolHave participated in another research study within 30 days preceding the commencement of this studyHave a history or presence of gastrointestinal, renal or hepatic disease of any causeAre taking any medication or food that is likely to affect the plasma cholesterol such as laxatives containing psyllium, antibiotics, probiotics or sterol-containing margarines.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Volunteers will be randomly allocated by computer generated sequence to study treatments. The treatments are coded numerically. Locked computer files indicate treatment allocation numerically and the treatment code is concealed from research staff.</concealment>
    <sequence>Volunteers will be initially blocked matched into 2 groups based on age, body mass index and gender, cholesterol level prior to randomisation by computer generated sequence</sequence>
    <masking>Open (masking not used)</masking>
    <assignment>Crossover</assignment>
    <designfeatures>2 week run-in followed by 12 week intervention</designfeatures>
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate>21/08/2006</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>30</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Government body</primarysponsortype>
    <primarysponsorname>Commonwealth Scientific Industrial Research Organisation, Human Nutrition</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>Commonwealth Scientific Industrial Research Organisation</fundingname>
      <fundingaddress />
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname>Nil</sponsorname>
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>To discover if the consumption of foods made from CSIRO barley leads to changes in the levels of substances in the plasma (such as cholesterol) that would suggest they are beneficial for heart health.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>CSIRO Human Nutrition</ethicname>
      <ethicaddress />
      <ethicapprovaldate>22/06/2006</ethicapprovaldate>
      <hrec>06/13</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Dr David Topping</name>
      <address>CSIRO Human Nutrition
PO Box 10041
Adelaide BC SA 5000</address>
      <phone>+61 8 83038930</phone>
      <fax>+61 8 8303 8899</fax>
      <email>david.topping@csiro.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Anne McGuffin</name>
      <address>CSIRO Human Nutrition
PO Box 10041
Adelaide BC SA 5000</address>
      <phone>+61 8 83038988</phone>
      <fax>+61 8 8303 8899</fax>
      <email>anne.mcguffin@csiro.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>